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140 Poster Session IIby day 4 as efficiently as wt B6 T cells, with a similar reduction in
pEC viability, from 93 6 6.7 to 43 6 6.4 in the presence of gld T
cells and 446 8.6 in the presence of wt B6 T cells (p . 0.5). How-
ever, upregulation of Fas on pEC co-cultured with gld T cells was
delayed and seen only by day 4 rather than day 2. The capacity of
gld T cells to modulate the epithelial environment appears intact,
since they induced the upregulation of H2Kb by 10-fold and IAb
by 3-fold on the pEC, similar to the effect induced by wt B6 T cells.
We also found higher interferon gamma (IFNg) in the supernatants
of co-cultures with gld T cells (141.26 17.8), as compared to wt B6
T cells (100.3 6 20.1, p\ 0.004). However, in contrast to the ex-
pression of H2Kb and IAb which were up-regulated 5.5-fold and
2.8-fold by IFNg added to pEC cultures, Fas expression was not al-
tered by this cytokine even after 7 days and at high doses (50 and 500
ng/ml). In summary, T cells increased the expression of Fas on
miHA-mismatched pEC. This event was of no evident conse-
quence, since FasL expression on ‘‘donor’’ T cells was not required
to kill ‘‘host’’ pEC in the 4-day period studied. FasL-deficient T
cells also modulated the expression of epithelial MHC molecules
and might be associated with the high levels of IFNg, a key cytokine
during GVHD, detected in supernatants of co-cultures. However,
IFNg did not regulate Fas on pEC, indicating that other cyto-
kines/mechanisms are responsible for this effect. Altogether, our re-
sults suggest that the Fas-FasL pathway may have a minor role in
the early pathogenesis of cutaneous GVHD.384
DACLIZUMAB AND INFLIXIMAB FOR TREATMENT OF STEROID RESIS-
TANT ACUTE GRAFT VERSUS HOST DISEASE (aGVHD) IN PEDIATRICS
Snyder, R.L., Daum, C., Klinger, E., Neudorf, S., Simpson, L. Children’s
Hospital of Orange County, Orange, CA.
Patients with steroid resistant aGVHD have a poor prognosis.
Daclizumab (anti-IL2 receptor alpha chain), and infliximab (anti-
TNF) have shown activity in early clinical trials in adults. We are
reporting our experience using daclizumab and infliximab in 3 pedi-
atric patients. All received daclizumab (1 mg/kg/dose IV on days 1,
4, 8, 15 and 22 and infliximab (10 mg/kg/dose IV on days 1, 8, 15
and 22). Steroid tapering was at the discretion of the attending phy-
sician based on clinical condition and response to treatment.
UPN 377 was a 19 month old girl with Hemophagocytic Lym-
phohistiocytosis who received a related bone marrow graft matched
for 8/8 alleles. She received a preparative therapy consisting of bu-
sulfan, VP16 and cytoxan and methotrexate (mtx) and cyclosporine
(csa) for GVHD prophylaxis. She developed stage 3 grade 2
aGVHD of the skin on d1 32 post transplant. After 19 days of ste-
roids (2 mg/kg/day), daclizumab and infliximab were started.
GVHD improved by d 1 36. The patient developed extensive
chronicGVHDand is presently 522 days post transplantwith aLan-
sky score of 100%.
UPN 394 was an 8 yr old male with ALL in CR2 who received
a related bone marrow graft matched for 5/8 alleles. He received
TBI, VP16 and cytoxan and mtx and csa for GVHD prophylaxis.
He developed stage 3 grade 2 aGVHD of the skin on d 1 24 post
transplant. After 2 days of steroids (4 mg/kg/day), he was treated
with daclizumab and infliximab. GVHD improved by d 1 31.
The patient has extensive chronic GVHD. He is 210 days post
transplant and has a Lansky score of 100%.
UPN 395 was a 13 month old male with ALL in CR1 who re-
ceived an unrelated bone marrow graft matched for 8/8 alleles.
He received TBI, VP16 and cytoxan and csa and mtx for GVHD
prophylaxis. He developed stage 3 grade 2 aGVHD of the skin on
d 1 19 post transplant. After 11 days of steroids (2 mg/kg/day),
he was treated with daclizumab and infliximab. GVHD improved
by d 1 33. The patient relapsed at d 1 189 post transplant and
has no signs of chronic GVHD.
In all patients, there were no instances of opportunistic viral or
fungal infections. This small series suggests that the combination
of daclizumab and infliximab is well tolerated and an effective ther-
apy for steroid resistant GVHD in pediatrics. Therefore, we have
revised our algorithm for the management of aGVHD (to be dis-
played at the meeting).385
MONOCYTE BLOOD COUNT AND ACUTE GVHD: FLOW CYTOMETRY
ANALYSIS RECOMMENDED IN PROSPECTIVE STUDIES
Chunduri, S.1, Arpinati, M.2, Singh, V.3, Shuaipaj, T.1, Mehta, J.3,
Rondelli, D.1. 1University of Illinois at Chicago, Chicago, IL; 2University
of Bologna, Bologna, Italy; 3Northwestern University, Chicago, IL.
Patients with a high absolute number of peripheral bloodCD141
monocytes prior to starting the conditioning regimen have been
shown to have a greater risk of developing acute graft-versus-host
disease (aGVHD) (Arpinati et al. BBMT 2007) after allogeneic he-
matopoietic stem cell transplantation (HSCT). In this study, we ini-
tially pooled the data of 154 consecutive patients with hematologic
malignancies who received an allogeneic peripheral blood stem cell
transplant at three different institutions, utilizing myeloablative (n
5 36) or reduced intensity conditioning (n5 118) regimens not in-
cluding ATG. The blood absolute monocyte count (AMC) was as-
sessed before starting the conditioning regimen and it was
calculated by dividing the absolute white cell count by the percent-
age of monocytes obtained with an automated CBC. The median
value of AMC in the study was 0.5  109/L (range:0.0–11.8). Of
154 patients, 73 had\ 0.5 and 81 had $0.5 AMC  109/L prior
to starting the conditioning regimen. All the patients received an
8/8 HLA antigen matched graft from related (n5 114) or unrelated
(n 5 40) donors. In the group of patients with lower AMC the me-
dian age was 51 (range:19–71) and donors were unrelated in 27%
and sexmismatched in 41%of the cases, whereas in the group of pa-
tients with higher AMC median age was 50 (range:18–63) and do-
nors were unrelated in 25% and sex mismatched in 36% of the
cases. The rate of acute GVHD grade II-IV in patients with low
or high AMC was 44% and 38%, respectively (p5ns). To test
whether the AMC obtained by means of automated CBC was com-
parable to the absolute count of CD141 monocytes detected by
flow cytometry, blood samples from 43 patients were analyzed uti-
lizing both techniques. In this series of patients, mean values of
AMC and CD141 blood cells were 11.9 6 11.9 and 7.3 6 6.9 
109/L and median values were 9.6 (range 95% CI:8.2–15.6) and
6.0 (range 95% CI:5.2–9.5)  109/L, respectively, (p 5 0.0004).
In this study, the analysis of monocyte absolute count by automated
CBC did not confirm the correlation between high levels of blood
CD141 cells analyzed by flow cytometry and development of
aGVHD. Since we demonstrate here that the absolute number of
monocytes obtained by cytofluorimetric expression of CD14 is sig-
nificantly different as compared to that obtained by automated
CBC, future prospective studies addressing the prognostic role of
monocyte blood count in allogeneic HSCT should be performed
utilizing a flow cytometry-based method.386
SIROLIMUS IN COMBINATION WITH CYCLOSPORINE OR TACROLIMUS
PLUS METHOTREXATE FOR GRAFT-VERSUS-HOST DISEASE (GVHD)
PROPHYLAXIS AFTER HEMATOPOIETIC CELL TRANSPLANTATION
FROM UNRELATED DONORS
Furlong, T., Kiem, H.-P., Appelbaum, F.R., Carpenter, P.A., Deeg, J.,
Doney, K., Flowers, M.E.D., Mielcarek, M., Nash, R.A., Storb, R.,
Martin, P.J. Fred Hutchinson Cancer Research Center, Seattle, WA.
Sirolimus (SIR) is reported to be effective in preventing GVHD
when combined with tacrolimus (TAC) and methotrexate (MTX)
after related and unrelated allogeneic hematopoietic cell transplan-
tation (HCT). In two consecutive clinical trials, we evaluated the ef-
ficacy of SIR plus cyclosporine (CSPGroup) or TAC (TACGroup)
and MTX after unrelated HCT. SIR was administered as a 12 mg
PO loading dose on day -1 (CSP Group) or -3 (TAC Group) fol-
lowed by 4 mg PO QD. SIR levels were targeted at 4–14 ng/mL
in the CSP Group and 3–12 ng/mL in the TAC Group. The dose
of CSP was 1.5 mg/kg Q12h IV starting on day -1, and the dose
of TACwas 0.02mg/kg/day IV starting on day -3. CSPwas targeted
at 150–450 ng/mL and TAC at 5–10 ng/mL. All patients received
MTX 5 mg/m2 IV on days 1, 3, 6 and 11. Nine patients were
